A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066

Article abstract of DOI:10.1016/j.bmc.2017.04.037

Recently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discov

Full text of DOI:10.1016/j.bmc.2017.04.037

Accepted Manuscript
A fragment-based approach leading to the discovery of a novel binding site and
the selective CK2 inhibitor CAM4066
Claudia De Fusco, Paul Brear, Jessica Iegre, Kathy Hadje Georgiou, Hannah F.
Sore, Marko Hyvönen, David R. Spring
PII:
S0968-0896(16)31479-1
DOI:
http://dx.doi.org/10.1016/j.bmc.2017.04.037
BMC 13707
Reference:
Bioorganic & Medicinal Chemistry
To appear in:
Received Date:
Revised Date:
Accepted Date:
21 December 2016
21 April 2017
27 April 2017
Please cite this article as: De Fusco, C., Brear, P., Iegre, J., Georgiou, K.H., Sore, H.F., Hyvönen, M., Spring, D.R.,
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor
CAM4066, Bioorganic & Medicinal Chemistry (2017), doi: http://dx.doi.org/10.1016/j.bmc.2017.04.037
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Bioorganic & Medicinal Chemistry
journal homepage: www.els evier.com
A fragment-based approach leading to the discovery of a novel
binding site and the selective CK2 inhibitor CAM4066
Claudia De Fusco,†a Paul Brear,†b Jessica Iegre,a Kathy Hadje Georgiou,a Hannah F. Sore,a Marko
Hyvӧnen,*b David R. Spring*a
aDepartment of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
bDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK
†Theseauthors contributed equally to this work
ARTICLE INFO
ABSTRACT
Article history:
Received
Received in revised form
Accepted
Recently we reported the discovery of a potent and selective CK2α inhibitor
CAM4066. This compound inhibits CK2 activity by exploiting a pocket located
outside the ATP binding site (αD pocket). Here we describe in detail the journey that
led to the discovery of CAM4066 using the challenging fragment linking strategy.
Specifically, we aimed to develop inhibitors by linking a high-affinity fragment
anchored in the αD site to a weakly binding warhead fragment occupying the ATP
site. Moreover, we describe the remarkable impact that molecular modelling had on
the development of this novel chemical tool. The work described herein shows
potential for the development of a novel class of CK2 inhibitors.
Available online
Keywords:
CK2;
Fragment-based drug discovery;
Kinase inhibition;
Fragment linking:
Molecular modelling
2009 Elsevier Ltd. All rights reserved
.
1. Introduction
1.1 Fragment-based drug discovery
Fragment-based drug discovery (FBDD) is a structure-based approach used to provide lead compounds to target biological systems.
Although initial hits usually have lower potency than those derived from High-Throughput Screening campaigns (HTS), FBDD is
considered to be more efficient in the optimization phases of drug discovery.1,2 In a typical FBDD project, a fragment library is
screened using sensitive biophysical techniques. Secondly, X-ray crystallography or NMR are used to investigate the binding modes of
the fragment hits in the protein of interest and thereby characterise the fragments’ binding pose.1-3 The third step is fragment
elaboration, typically occurring via growing, merging and/or linking strategies. In the growing strategy optimised fragment hit is grown
in a step-wise fashion, engaging with the target through additional interactions.3 The merging strategy sees the best features of several
overlapping fragments merged into single molecule with higher potency.3 In the linking strategy, fragments binding in different parts of
the target site are linked together via rigid or flexible linkers.4 The linked compound should have a more favourable ∆G of binding than
the sum of the ∆G values of the individual fragments according to the concept of ‘super-additivity’.5-7 However this last strategy has
been considered to be the most difficult of the three methods applied in FBDD .3 Ideally, the linker should maintain the optimal binding
configurations that have been adopted by the individual fragments and should establish additional interactions with the protein to
prevent a loss in ligand efficacy (LE).3 In practise the linkers often constrain the molecule too much resulting in suboptimal interactions
with the target.
1.2 CK2 as an anticancer target
CK2 is a hetero-tetrameric enzyme composed of two catalytic subunits (α and/or α’) and two regulatory subunits (β and/or β’) which
confer stability, control selectivity and enhance enzyme activity.6,7 It is an unusual kinase in that it is believed to be constitutively
active, without needing external stimulus, such as phosphorylation of the activation loop.
CK2 is involved in multiple intracellular pathways including the regulation of cell proliferation and cell growth. It is also believed to be
an apoptosis-suppressor in both healthy and cancer cells.8,9
Among other features, cancer cells show dysregulated proliferation and apoptotic activity leading to uncontrolled cell growth.10 CK2
has been found to be overexpressed in a range of cancer cell lines including prostate, breast, colon cancer.11 As reported by Trembley
and co-workers, the dysregulated expression of CK2 in cancer cells is an index of the pathological status of the tumour. Their studies
have also shown that downregulation of CK2 decreases cell growth and cell proliferation and increases apoptotic activity.12 Therefore,
FBDD Fragment-Based Drug Discovery, NMR Nuclear Magnetic Resonance, LE ligand efficiency

CK2 is crucial for cell survival, and the absence of redundant pathways to compensate for its downregulation makes cancer cells more
sensitive to CK2 inhibition.11,12 Hence, CK2 inhibition represents an attractive anticancer target.
6,13-14
The most common strategy to inhibit CK2 is through small molecules that target the ATP-binding catalytic site.
However, a
drawback of ATP competitive inhibitors is that they suffer from selectivity issues, leading to off-target effects.9,15
Therefore, as with other kinases, increased interest has arisen in the development of inhibitors that do not target the conserved ATP site
and demonstrate better selectivity. CK2 inhibition exploiting allosteric binding sites has been achieved using a variety of approaches
which target CK2 substrates,16 the regulatory β subunit17 or the α/β interface.18–21
Recently, we reported the discovery of a new binding pocket, the αD site, within the catalytic CK2α subunit and described the
development of a novel class of inhibitors of CK2α utilising this pocket (CAM4066). CAM4066 has nanomolar affinity for CK2α and
clearly increased selectivity relatively to other known CK2 inhibitors.22
Herein we present in detail the optimization of the initial fragment bound in the αD pocket into the selective inhibitor CAM4066 by the
successful combination of fragment growing and linking.
2. Material and methods
2.1 Chemistry
2.1.1 Experimental procedures
Compounds 3-5 were obtained from the commercially available 3-chloro-4-hydroxy-benzonitrile via the synthetic route reported in
Scheme 1.
Scheme 1. (a) DMF, RX, Na2CO3, (b) i) LiAlH4, Et2O, AlCl3, ii) Et2O, 2 M HCl in Et2O. General procedures are detailed in the Supporting Information.
Synthesis of 6 and 7 was obtained starting from aryl triflation of 3-chloro-4-hydroxy-benzonitrile to give compound 6a which then
underwent Suzuki-Miyaura cross-coupling to provide compounds 6b and 7a followed by nitrile reduction. Conversion of the amines
into hydrochloride salts provided the biaryls 6 and 7 as shown in Scheme 2.
Scheme 2. (a) CH2Cl2, Py, Tf2O, (b) ArB(OH)2, LiCl, DCE, Pd(PPh3)4, (c) i) LiAlH4, Et2O, AlCl3, ii) Et2O, 2 M HCl in Et2O.
General procedures are detailed in the Supporting Information.
Compounds 10-18 were prepared by the general method in Scheme 3. Compound 10b, which was obtained via Suzuki coupling of 10a
and phenylboronic acid, underwent reductive amination with the appropriate amines and then treated with hydrochloric acid to provide
the final compounds.

+
Scheme 3. (a) CH2Cl2, Py, Tf2O, (b) ArB(OH)2, LiCl, DCE, Pd(PPh3)4, (c) compounds 10, 12-15: RNH2, DCE, NaBH(OAc)3, (d) compounds 11, 16-18: RNH3
,
MeOH, Et3N, NaBH(OAc)3, (e) Et2O, 2 M HCl in Et2O. General procedures are detailed in the Supporting Information.
Compound 20 was synthesised by methyl ester hydrolysis of its precursor 19. The synthesis of 19 started from treatment of the
commercially available N-Boc-1,3-propanediamine with methyl 3-chloro-3-oxopropionate to provide 20a which was then converted to
the TFA salt 20b. Compound 20b underwent reductive amination in the presence of 10b to give 20c (Scheme 4).
Scheme 4. (a) CH2Cl2, 3-chloro-3-oxoproprionate, NaHCO3, (b) TFA/ CH2Cl2, (c) MeOH, Et3N, NaBH(OAc)3, (d) LiOH,THF, 4 M HCl in dioxane, CH2Cl2.
General procedures are detailed in the Supporting Information.
Synthesis of 21 commenced with ester hydrolysis of 20a followed by coupling with commercially available m-amino benzoate to give
21c. The latter intermediate underwent reductive amination to provide 21d which was then hydrolysed to obtain 21 (Scheme 5).

Scheme 5. (a) LiOH,THF, 4 M HCl in dioxane, CH2Cl2, (b) EDC-HCl, NMM, (c) RNH3+, MeOH, Et3N, NaBH(OAc)3, (d) LiOH,THF, 4 M HCl in dioxane.
General procedures are detailed in the Supporting Information.
2.1.2 Detailed procedures and characterization
Detailed procedures and characterization of all the compounds reported in the paper and their precursors can be found in the Supporting
Information.
2.2 Biophysical assays
2.2.1 Protein expression and purification, X-ray crystallography, Phosphorylation assays, ITC
Protein expression and purification, X-ray crystallography, phosphorylation assays and ITC protocols can be found in the Supporting
Information of our recently published paper.22
2.3 Molecular modelling
Molecular modelling was performed using Glide from the Schroedinger package using default parameters.23–25 Details can be found in
the Supporting Information.
3. Results and discussion
Since it had previously been reported that the α/β interface could be used for the allosteric inhibition of CK2α,7,20,21 we decided to target
the α/β interface using FBDD. We ran a fragment screen targeting α/β interface on the catalytic CK2α subunit and identified a number
of fragments binding to this site. While we were optimising the fragment hits on the α/β interface, one of the fragment analogues
revealed a previously unseen pocket near the ATP-binding site, suggesting a novel and effective method of inhibiting CK2α (Figure 1).
The first inhibitor to utilise this newly identified pocket was CAM4066, a nanomolar inhibitor with good selectivity for CK2α.22

Figure 1. Overview of the workflow from fragment screening against the α-β interface of CK2 to the discovery of a novel binding site and development of
CAM4066.
3.1. Fragment screening to find hits to target CK2
As reported previously, 1 was observed in crystal structures bound to multiple sites on CK2α during a fragment-screening program
against CK2 (Figure 2).22 Three of these sites were at crystal contacts and therefore of little interest, but the other three sites were of
biological significance. Electron density for the ligand was observed at the CK2α/β interface, in the ATP-binding active site and, most
unexpectedly, at a previously unreported site located behind the αD helix, which we have named the αD site. This site is formed by the
movement of the flexible αD helix which opens up a deep hydrophobic pocket adjacent to the ATP site. The αD helix is significantly
more flexible in CK2α than in any other kinases and as such is seen to adopt multiple positions in different crystal structures. There are
3 reported apo structures; the closed conformation, where the αD pocket is filled by Phe121 (PDB:3FWQ), the partially open
conformation (5CVH) where Tyr125 partially fills the pocket and an inactive conformation where the αD pocket is filled by leu124
(PDB:5CVG) which distorts the hinge region and prevents ATP binding. To allow the binding of 1 the residue that fills the αD site in
the different apo forms (Leu124, Tyr125 or Phe121) is displaced and Met225 rotates opening the bottom of the αD site. The amine of
the fragment forms hydrogen bonds with the backbone carbonyl of Pro159, two waters at the top of the pocket and forms possible π-
cation interactions with Phe121. The dichlorophenyl part of the fragment sits deep in the pocket interacting with hydrophobic core of
the pocket, exposed when Met225 moves out of the pocket.

Figure 2. a) Crystallographic structure of CK2α (grey) and 6 molecules of 1 (green). The promiscuous fragment occupies various sites of the protein showing
potential for allosteric inhibitors (PDB code 5CLP). The molecules occupying biologically relevant sites are highlighted by sphere representation. The molecules
at crystal contacts and therefore not of interest are shown as sticks. b) The movement of the important residues in the αD site upon the binding of 1 (pdb:5CLP)
compared to the partly open apo structure (pdb:5CVH). c) The movement of the important residues in the αD site upon the binding of 1 (pdb:5CLP) compared to
the closed apo structure (pdb:3FWQ) d) The movement of the important residues in the αD site upon the binding of 1 (pdb:5CLP) compared to the inactive
structure (pdb:5CVG).
3.2. Lead generation
Prior to conducting any studies to assess the potential of the αD site, a chemical tool to probe the αD site had to be developed from 1,
given that it bound weakly to multiple sites and therefore was of no use to probe the function of one site. The initial plan was to pursue
a fragment linking strategy in order to quickly develop inhibitors that would bind at the αD site but inhibit by linking to fragments in the
ATP site. This strategy would have 4 phases;
1. Fragment optimisation: The aim was to develop fragments with a higher affinity and selectivity for the αD site than 1, as 1 was found
binding to a number of different sites and hence thought to be less than ideal as a starting point for the development of specific
inhibitor.
2. ATP site fragment identification: Warhead fragments bound in the ATP site would be identified using X-ray fragment screening.
Ideally, such fragment would interact with the ATP site only weakly so that the affinity for CK2α would be dominated by the affinity
for the non-conserved αD site and thus drive selectivity and ATP site warhead would provide only steric hindrance to displace the
nucleotide from the kinase. The chosen fragment would also contain a suitable chemical functionality in a correct position for linker
attachment.
3. Linker optimisation: Fragment linking is seen as the more challenging route of fragment optimisation as introducing a linker that
does not interfere with the binding mode of the original fragments is difficult. Therefore, the optimised αD site fragment would be
iteratively grown towards the ATP site in an attempt to generate an efficient linker.
4. Fragment linking: Finally, the optimised αD site fragment would be linked to the weakly binding ATP site fragment using the
knowledge gained from the linker optimisation to give the final chemical tool which will be used to probe the potential of the αD site to
develop selective CK2α inhibitors.

3.2.1 Fragment optimisation
Promiscuity was a particularly acute problem with the original fragment 1 as it was observed to bind to the ATP site, the interface and
the αD site. Therefore, the initial aim was to identify more selective αD binding fragment, at the expense of the ATP and α−β interface
sites.
Firstly, commercially available analogues of 1, identified from the Zinc database,26 were screened in-silico against the αD site. From
this screen, a number of commercially available compounds were purchased and co-crystal structures were obtained to determine the
binding mode. These compounds explored a range of structures around the initial fragment and included variations in the distance from
the hydrophobic core to the amine group as well as changes in the substitution pattern at the 3 and 4 positions (Figure 3).
Figure 3. Schematic representation of the fragment elaboration carried out around 1 to develop a lead fragment to inhibit CK2.
Analysis of the structure of 1 bound to CK2α indicated that the amine provided vital hydrogen bonds with the backbone carbonyls of
Val162 and Pro159 at the mouth of the pocket (Figures 4a and c). The crystal structure of 2 (Figure 4d), bearing a trifluoromethoxy
group in the 4-position and a shorter linker to the amine, showed that the compound bound selectively in the αD site and appears to bind
neither to the ATP nor the interface sites. As predicted, the amine of 2 retained the interactions with the backbone carbonyls of Pro159
and Val162. The crystal structures indicated that there was space for optimization around the OCF3 group of 2 (Figure 4d). Therefore,
the subsequent optimization of 2 focused upon the modification of the 4-position of the benzyl ring in order to increase affinity for the
bottom of the αD site.
Based on the crystal structure of 2, a series of fragments with modifications in the 4 position were designed in silico and synthesised (3-
7, Table 1)). All 5 of these fragments were soaked into CK2α crystals and their complex structures determined. These structures
showed that all new fragments bound as predicted, in the αD site, with 6 and 7 showing some weak density at the α/β interface site. The
R-groups in the 4 position all filled the pocket formed by the movement of Met225. However, the electron density for the groups in the
4 position was poorly defined for all groups apart from those in 6 and 7 in which the phenyl group or furan group stacks against
Met225. The structures of all of these compounds showed that the binding of the fragments caused a significant movement of the αD
loop but by different amounts in each structure (Figure 4f). In the co-crystal structure of 1 and CK2α_FP10 (Figure 4f, blue), a small
movement of 3 Å brings Tyr125 out from being buried underneath the αD loop and allows the fragment to bind. However, when 4
bound a greater displacement of the loop by 24 Å occurred, which led to a subsequent increase in the size of the αD pocket (Figure 4f,
dark blue). It was unclear as to why the loop moved significantly more in the structure of 4, however, it is likely that in solution the αD
loop is flexible and free to move upon the binding of the fragments but the crystal structures only capture one of a range a of possible
conformations. The affinities of these fragments towards the αD pocket was then determined by ITC (Table 1)
(Fragment_aD_site_optimisation.pse Here).
Table 1: Structures and Kd values of the fragments showing selective binding in the αD pocket over the ATP site and the interface.
NH3+Cl-
Cl
R
Affinity
(ITC)
Structure
R =
Compound
PDB
Kd (µM)
2
-OCF3
NA
5CVF

3
4
5
6
7
300
629
500
520
270
5MOD
5CS6
5MOE
5CSH

Figure 4. The optimisation of the αD site fragment. a) The interactions of the amine of 1 with the backbone carbonyls of Val162 and Pro159 along with the
interaction with Asn118 and Asn119 via a water bridge (PDB: 5CLP). b) The interactions of the amine of 7 with the backbone carbonyls of Val162 and Pro159
along with the interaction with Asn118 and Asn119 via a water bridge (PDB: 5CHS). Since the amine of 7 sits higher up in the pocket, it pulls down the top
water into hydrogen bonding distance, thereby forming another water bridge to Asn118. c) The hydrophobic core of 1 sits in the hydrophobic pocket of the αD
site (PDB: 5CLP), however there is still potential to optimise the interactions with this pocket. d) From the crystal structure it appears that 2 is more selective for
the αD site over the ATP site, however, the OCF3 group does not fill the hydrophobic pocket of the αD site (PDB: 5CVF). e) The crystal structure of 7 bound in
the αD site shows that the molecule fills the hydrophobic core of the αD pocket more efficiently (PDB: 5CHS). f) Movement of the αD loop upon binding of
compounds 1 (green), 2 (magenta), 3 (cyan) and 4 (light blue).
The crystal structures and binding affinities of the fragments showed that 7 was the most interesting of these fragments. It binds with
the phenyl group deep in the hydrophobic αD site and had the highest affinity of 270 µM (co-crystal structure shown in Figures 4b and
e). However, these compounds did not show any inhibition of the kinase activity of CK2α as they were not binding in the ATP site.
Indeed, no electron density corresponding to any of the compounds from this stage was observed in the ATP site and good electron

density for ADP or ATP was observed in the ATP sites with 6 or 7 bound. This data led to 7 being selected as the optimised αD site
fragment for further elaboration.
3.2.2 ATP site fragment identification
In order to obtain a suitable fragment to use as the warhead in the ATP site, a 352 member fragment library, optimised for X-ray
screening (purchased from Zenobia), was screened against CK2α. The screening was performed by soaking the fragments into crystals
as cocktails of four fragments. Of these, 23 fragments showed weak electron density in the ATP site. These compounds could be
divided into 3 groups, based on their binding mode: hinge binders (2 fragments, pdb:5MOT and 5MOW), Lys69 binders (11 fragments,
for example pdb:5MOH and 5MOV) and fragments that interact with both the hinge region and Lys69 (10 fragments, example
pdb:5CSV and 5CSP). The hinge region is very conserved amongst kinases27 (Figure SI_1, Supporting Information) and as such
fragments binding to the hinge would interact with many other kinases. We therefore focused our efforts on the Lys69 binding
fragments. Fragments interacting with Lys69 were dominated by structures with a benzoic acid core with the carboxylic acid interacting
with terminal amine of Lys69, similarly to what is seen with well characterised CK2α inhibitor CX-4945.These compounds were
ranked using a thermal shift assay (results can be found in the Supporting Information), as we had previously observed that the thermal
shift assay was effective for detecting ATP site binding ligands (unpublished data). These compounds gave shifts of between 0 and
+4.1°C and the data confirmed that the benzoic acid core was a promising fragment to procced with. One of the compounds (9) that
gave the highest shift was then further investigated in a phosphorylation inhibition assay and its Kd determined via ITC. This showed
Compound 9 has a Kd of 58 µM (Figure 5) and that its inhibition in the phosphorylation assay was approximately 100 µM.
However, although 9 had for a fragment a very high affinity, it was not chosen as the ATP site fragment for a number of reasons.
Firstly, the aim was to validate the concept of using the αD site to develop a selective CK2α inhibitor and therefore the affinity for
CK2α must be dominated by binding in the αD site rather than the ATP site. Secondly, 9 did not contain a synthetically tractable handle
in the position we envisioned linking to.
We therefore re-examined the remaining benzoic acid fragments that interacted only with Lys69. Inspection of the crystal structure and
investigation of the affinity of Fragment 8 for CK2α showed it fulfilled all the criteria set out for a suitable fragment: it did not interact
with the hinge region, it had very low affinity (>500 µM) and it contained a suitable synthetic handle for linking into αD binding
compounds (Figure 5). Therefore 8 was chosen as the fragment to link to in the ATP site, however, this choice would be evaluated
again once the linker was developed further.
Figure 5. Electron density of fragments 8 (PDB code 5CSP) and 9 (PDB code 5CSV) in the ATP binding site. The protein is represented in cyan and the H-bond
between the fragments and the protein is shown as a black dashed line.
3.2.3 Linker Optimisation
With the optimised anchor fragment 7 and the ATP site-binding warhead 8 in hand, the challenge was to develop a suitable linker to
unite the two fragments. Fragment linking is seen as a promising technique for fragment optimisation due the possibility of super-

additivity, but it is rarely fully successful due to the many challenges in the design of the linker. Whittaker and co-workers suggested
that for the highest chance of success, the binding of one of the starting fragments should be dominated by polar interactions and the
other by hydrophobic interactions as this allows greater flexibility in the binding mode of one of the partners.28 This was promising in
our case since the binding of the benzoic acid 8 is dominated by polar interactions in the ATP site and 7 binds to the largely
hydrophobic αD pocket. The amine of 7 was the best point to grow out of the αD pocket towards the ATP site with the aim of linking to
the amine of 8. The initial modelling studies indicated that the minimum length required to link 7 and 8 would be nine atoms (Figure 6).
However, the length of this linker was envisioned to be a problem as high flexibility is a well-established unwanted characteristic in
inhibitor development.29 Therefore, rather than simply linking the two fragments it was decided to iteratively grow 7 out of the αD site
in an attempt to generate a linker that interacted with the target while extending towards the ATP site. To this end, a series of analogues
of 7 were synthesized with variations at the amine, thereby growing out of the αD pocket towards the ATP site (Table 2). This process
was guided by continuous structural analysis of the binding mode followed by analysis of the compounds ability to inhibit in the
phosphorylation assay and determination of its affinity by ITC. (Linker_optimisation.pse Here)
Figure 6. Modelling studies of potential linkers connecting fragments 7 and 8: a) A 9-atom linker needed to link the ATP site and the αD site.
b) The proposed linker seen from above. Original fragments, as observed in crystal structures are highlighted with red and blue and the modelled linker if shows
as semitransparent sticks.
Table 2: Structure and % inhibition of kinase activity at 500 μM of all the compounds with variable length linkers.
% Inhibition
at 500 μM
Compound
R
PDB
10
5MP8
44 12
11
5MPJ
23 6

12
13
14
15
16
17
18
19
5MMF
5CTO
5MMR
5CTP
5MO7
a
33 5
47 5
18±2
39
3
16 6
12 4
51 10
46 2
20 4
5MO5
5CU2
5MO6
20
a Poor or no electron density observed for the ligand.
Initially, aliphatic chains of different length were investigated to establish the tolerance of the linker channel to different substituents.
The methyl and ethyl groups of compound 10 and 11 occupied a small lateral pocket, however, 11 exhibits two conformations one of
which occupied the channel that links the αD site and ATP site. Therefore, the chain was extended further as in 12. In this compound
the three-carbon atom linker no longer occupied the lateral pocket but bound only in the channel formed by Met163. Interestingly, in
the crystal structures with either 10 or 11 bound in the αD site, ADP was visible in the ATP site, whereas when 12 bound, the
nucleotide was no longer visible. However, this was not reflected in the inhibition observed as all three compounds showed only weak
inhibition of phosphorylation by CK2α.
The linker was then further expanded to incorporate various hydrogen bonding groups including hydroxyl (13), amine (14), amides (15-
17) and sulfonyl amide (18) moieties. The X-ray structure of compound 13 showed the trajectory of the linker was still away from the
target region of the ATP site (Figure 7a and b). However, when an amide or sulfonyl amide were incorporated in this position or an
amine with a four carbon linker (compounds 14-17), the side chain of Met163 changed its conformation, turning into the ATP site
(Figure 7a). This movement opened a small channel between the αD site and the ATP site for the linker, with the amide nitrogen
forming a hydrogen bond to the backbone carbonyl of His160 and the amide stacking against His160 (figure 7a). More importantly, the
linker was now extending towards the desired region of the ATP site. This new channel effectively cut the corner between the αD site
and the ATP site and would allow the use of shorter and more efficient linkers. Indeed, modelling of linkers now indicated that only a
seven atom linker would be required to link the two fragments together which is an important improvement on the initially proposed 9
atom linker (Figure 7d, e and f).

Figure 7. Conformational changes of linker channel. (a) The crystal structure of 13 (pdb:5CT0, pink) with 15 (pdb:5CTP, light blue) superimposed. When 13
binds, Met163 does not move therefore the channel to the ATP site does not open and the surface of CK2α is clearly seen to block the binding of 15. The linker
of 15 also forms a hydrogen bonding network with back bone carbonyls within the channel. b) The surface representation of the crystal structure of 13
(pdb:5CT0) bound to CK2α. c) The surface representation of the crystal structure of 19 (pdb:CX9, purple) bound to CK2α with the structure of 13 (pink)
superimposed. The outline of the surface when Met163 blocks the channel is represented by a red dotted line. d) Overlay of the modelled 7 atom (yellow) and 9
atom linkers on to the crystal structures of the fragments 7 (5CSH, light blue) and 8 (green) when Met163 has flipped to open the channel. The outline of the
surface when Met163 blocks the channel is shown as a red dashed line; e) Overlay of the modelled 7 atom linker (yellow) and 9 atom linker (dark blue) when
Met163 is flipped and forms the linker channel. The crystal structure of the ATP site binding fragment 8 is shown (green, 5CSP) The sides of the channel are
highlighted by a red dashed line; f) Overlay of the modelled 7 atom linker (yellow) and 9 atom linker (dark blue) when Met163 has not flipped and blocks the
linker channel. The crystal structure of the ATP site binding fragment 8 is shown (green, 5CSP)
.
Further elaboration of the linker led to molecules 19 and 20 that were suitable for linking with 8 (figure 7c). The affinity of these
extended compounds was determined by ITC, showing very similar Kd values of approximately 250 µM for both 19 and 20. Therefore,
despite making extensive contact with CK2α, the linker was not increasing the affinity for the protein, most likely due to its inherent
flexibility leading to a greater entropic penalty upon binding. The ligand efficiency therefore decreased significantly to 0.23 and 0.19
for 19 and 20, respectively.
3.2.4 Linking strategy
The information gained from the linker growth was then utilized in the linking of the optimised anchor 19 and the warhead 8 at the ATP
site. Analysis of the molecules growing from the aD pocket also confirmed our selection of the ATP site fragment. Change in the
conformation of the side chain of Met163, as induced by the optimal linker, changes the ATP pocket in the hinge region and would
affect the interaction of fragments in this region. As the linkers seemed not to induce conformational changes in the other side of the
ATP pocket, fragments interacting with Lys69 should be able to bind freely. Indeed, the superimposition of the crystal structure of 21,
a fragment from the Zenobia screen that interacts just with the hinge region of CK2α (figure 8a), onto the structure of the ATP site
when 19 binds to the αD site indicates that 21 would not bind simultaneously with the linker molecule 19 (figure 8b). Whereas, when 8,
which interacts with only Lys69 (figure 8c), is superimposed onto the structure of 19, Met163 does not appear to prevent its binding
(figure 8d). (ATP_site_fragments_Met163_movement.pse Here)

Figure 8. a) The crystal structure of 9, a hinge binding fragment, bound to CK2α. Met163 (green) is in the down position where it blocks the channel between the
αD site and the ATP site. b) The structure of 9 superimposed onto the structure of 19 where Met163 (blue) is flipped up and opens the channel between the αD
site and the ATP site. Met163 would in this position clash with ZT0432. c) The crystal structure of 8 bound to CK2α. Met163 (green) is in the down position
where it blocks the channel between the αD site and the ATP site. d) The structure of 8 superimposed onto the structure of 19 where Met163 (blue) is flipped up
and opens the channel between the αD site and the ATP site. Met163 does not clash with 8.
To confirm this hypothesis, the ATP site fragments 8 and 9 were both co-soaked into CK2α with compound 19. Unfortunately, the
crystals containing 8 did not give data with high enough resolution to be able to fit the ligand. On the other hand, crystal structures of 9
with 19 showed that the benzoic acid core fragment at the opposite end of the ATP site did not prevent the movement of Met163 and
thus the opening of the channel. The ester of the linker in 19 was slightly displaced compared to the structure without the fragment 9 as
the end of the linker bound in close proximity to the fragment (Figure 9). (Compound19.pse Here)
In addition, these structures confirmed that fragments that interacted with the hinge region would prevent the movement of Met163 and
would therefore not be optimal for linking from the αD pocket. Moreover, the co-soaked structures also confirmed the results from the
modelling studies that the best position to link to the benzoic acid core is the 3-position of the aromatic ring (Figure 8b). With these
results in hand, fragment 8 was confirmed to be the best warhead to be connected to 19 as a molecule carrying the anchor and the linker.

Figure 9. Optimisation of the linker between the αD pocket and the ATP site. a) and b) The structure of 19 and 9 (PDB: 5CU2), co-soaked into CK2α. The
surface of the channel when fragment 7 was bound in the αD pocket (PDB: 5CSH) is indicated by the red dashed line. The position of Met163 in the apo form is
shown (green). c) A more detailed view of the structure of 9 co-soaked with 19, showing the location of the putative sites of linking (yellow dashed line); (d) The
structure of 19 bound to CK2α showing the surface of the channel between the αD site and the ATP site formed by the movement of Met163.
3.3 CAM4066
The information gained from the linker optimisation process was then utilized in the final linking of 19 and 8. Initially, two linked
compounds were designed and synthesized (compound 21 and CAM4066). Both compounds contained a seven atom linker as this was
the required length established through the optimisation and design process, however, the position of the amide groups within the
linkers was varied. In order for compounds 19 and 8 to be linked together to provide the optimal inhibitor, the linker would have to
bend by 90° as 8 and 19 are in different planes (Figure 10a). It was also predicted that the position of the amide groups in compound 21
conferred undesired rigidity to the linker (Figure 10b). Modelling suggested that CAM4066, an amide isomer of 21, would be a valid
alternative as it would be able to retain a hydrogen bond network with the channel and, more importantly, it would not contain rigid
amides in the region of the linker where the greatest flexibility was required (Figure 10c). Both compounds were synthesized and co-
crystal structures of both compounds bound to CK2α showed that they successfully linked the two sites (Figure 10d and 10e).
d)
d)
e)
Figure 10. The flexibility of the 2 linked inhibitors. a) The ATP site fragment 8 and the linker 19 are out of plane with each other by approximately 90° which
makes successful linking more challenging. b) The various resonance forms of 21. The resonance forms impart rigidity to the linker in the position where
flexibility is required. This may account for the reduced affinity. c) The various resonance forms of CAM4066. The resonance forms allow flexibility to the
linker in the needed position. d) The binding conformation of 21 in CK2α. The highlighted areas are the rigid sections of the linker. e) The binding conformation
of CAM4066 in CK2α. The highlighted areas are the rigid sections of the linker.
The affinity of CAM4066 for CK2α was established to be significantly higher than that of 21, therefore, the validation focused upon
CAM4066 (CAM4066.pse Here). The lower activity of 21 was attributed to the rigidity of the amide groups where the linker was
required to be flexible (Figure 10). As previously reported, although CAM4066 was a potent CK2α inhibitor it had to be administered
as a pro-drug, pre-CAM4066, in order to gain activity in cell based assays. This was probably due to the zwitterionic nature of
CAM4066, which is often associated with poor cell permeability (Table 3).

Figure 11. The inhibition of the CK2 holoenzyme by CAM4066. a) The isotherm of CAM4066 binding to the CK2 holoenzyme. b) The inhibition of kinase
activity of the CK2 holoenzyme by CAM4066. c) The structure of the CK2 holoenzyme, CK2α is shown in blue and CK2β is shown in purple (pdb:4MD7)30
with the structure of CAM4066 binding to CK2α, shown in green, (pdb:5CU4)22 superimposed onto it. The position of the αD site is highlighted. d) A close up
view of several conformations of the αD loop observed in the CK2 holoenzyme crystal structures with the structure of CAM4066 bound to CK2α, shown in
green, (pdb:5CU4)22 superimposed on them. The closed conformation is shown in light blue (pdb:4MD7)30 the partly open form in yellow (pdb:1JWH)31 and the
open conformation, in which Tyr125 is mutated to Arg125 is shown in grey (4DGL)32
CAM4066 was then shown to be the most selective CK2α inhibitor discovered to date which validated the concept of developing
inhibitors that bound in the novel αD site. The pro-drug form, pre-CAM4066, was shown to exhibit good activity against various cell
lines and to inhibit the phosphorylation of various CK2α substrates confirming target engagement within the cell. The validation
process has been reported in detail in our previous work which focused on the inhibition of the catalytic subunit CK2α.22 Further to this
we have now confirmed that CAM4066 also inhibits and binds to CK2α when it is in a complex with its regulatory domain CK2β. The
CK2 holoenzyme was expressed and purified as described in the supplementary materials and the affinity of CK2α for CK2β was found
to be 14 nM, which is comparable with the previously reported value of 12.6 nM.33 The affinity of CAM4066 for the complex was
determined to be 0.31 µM by ITC (Figure 11a) and this value is similar to that reported for CAM4066 and the isolated catalytic subunit
of 0.32 µM. It was then confirmed that CAM4066 also inhibits the kinase activity of the CK2 holoenzyme using the previously reported
phosphorylation assay.22 This showed that CAM4066 inhibited phosphorylation by the complex with an IC50 similar to that of CK2α
(Figure 11b). The IC50 of CAM4066 against the complex is 0.67 0.29 µM whereas the IC50 against CK2α was 0.37 0.06 µM. Although
the IC50 against the complex was higher than the one of CK2α, the difference is not significant considering the error of the assay. This
data confirms that the formation of the complex does not prevent the opening of the αD pocket. This conclusion was predicted from
analysis of the various crystal structures of the CK2 complex superimposed on the structures of CAM4066 bound to CK2α (Figure 11c
and d). It can be clearly seen that the formation of the holoenzyme does not result in the formation of a protein-protein interface that
would block the opening of the αD pocket (figure 11c). Likewise, comparison of the various holoenzyme structures published indicates
that formation of the holoenzyme complex does not result in a reduction in the flexibility of the αD loop which would prevent the
opening of the αD pocket. As with the structures of CK2α both the closed (pdb:4MD7)30 and partly open (pdb: 1JWH)31 conformations of
the αD loop are observed in the wildtype holoenzyme complex structures indicating the loop retains its flexibility in the complex. It is
also worthy of note that when Tyr125 is mutated to Arg (pdb:4DGL)32 that the loop is observed in the open conformation, presumably

because it is unfavourable for the Arginine to fill the αD pocket. This strengthens the conclusion that it is possible for the pocket to open
in the holoenzyme as it indicates that the holoenzyme formation does not block the opening of the pocket or increase the rigidity of the
loop.
Table 3: Structures and IC50 of the final linked compounds.
Compound
Structure
Kd
IC50
PDB
21
1.64
n/a
5MO8
CAM4066
0.320 0.370 5CU4
Pre-CAM4066
n/a
n/a
N/D

4. Conclusions
In the present work we give a detailed description of fragment-based inhibitor development that utilised the
unforeseen discovery of a novel binding pocket on CK2α. The αD site was discovered by the serendipitous binding of
fragments in this new site. These fragments were first optimised to give a selective anchor in αD site that was then
linked to a weakly binding fragment in the ATP site which acted as the warhead to provide the inhibition. In order to
achieve the super additivity possible from linking fragments an extensive linker optimisation program was pursued to
identify the length and composition of the linker. The resulting compound vindicated this strategy of carefully
optimising the linker as the affinity of the final compound (320nM) was greater than could be expected from the
combination of two fragments with 250 µM and >500µM affinities. Although further work is required to improve this
chemical tool into a lead candidate, the discovery of CAM4066 has validated the concept of using the newly
discovered αD site to achieve selectivity. Furthermore, it showed a case of successfully applying a fragment linking
strategy which is known to be particularly challenging. In-silico molecular modelling was a remarkably beneficial tool
as, together with X-ray, it provided a means to development a suitable linker to attach the high-affinity molecule lying
in the αD pocket to the low-affinity fragment binding in the ATP site. Moreover, this work provided knowledge
regarding the new cryptic pocket and the linker channel, showing potential for the development of a new class of CK2
inhibitors.
Acknowledgments
We would like to thank all members of the Wellcome Trust Strategic Award team for useful discussions. We would like to
thank Dr Dima Chirgadze from the X-ray crystallographic facility, Dr Katherine Stott from the Biophysics facility at the
Department of Biochemistry and Victor Bolanos-Garcia for supplying the CK2β construct. We thank Diamond Light
Source for access to beamline IO2, IO3, IO4 and IO4-1 (proposals mx9537 and mx9007) and SOLEIL for access to
beamline Proxima 2. This work was funded by the Wellcome Trust Strategic (090340/Z/09/Z) and Pathfinder
(107714/Z/15/Z) Awards. The Spring lab acknowledges support from the European Research Council under the
European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no [279337/DOS]. In
addition, the group research was supported by grants from the Engineering and Physical Sciences Research Council,
Biotechnology and Biological Sciences Research Council, Medical Research Council, Royal Society and Welcome
Trust.CD thanks the Herchel Smith Funds for a postdoctoral fellowship. JI thanks Trinity College, Cambridge for a
PhD studentship. KH wishes to thank the Cambridge Trust and the Skye Foundation for a PhD scholarship.
References
1.
2.
Murray, C. W.; Rees, D. C. Nat. Chem. 2009, 1, 187–192.
Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: Leads by design. Drug Discov. Today
2005, 10, 987–992.
3.
4.
5.
Ciulli, A.; Abell, C. Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol. 2007, 18, 489–496.
Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Biochemistry 2012, 51, 4990–5003.
Nazaré, M.; Matter, H.; Will, D. W.; Wagner, M.; Urmann, M.; Czech, J.; Schreuder, H.; Bauer, A.; Ritter, K.; Wehner, V. Angew.
Chemie - Int. Ed. 2012, 51, 905–911.
6.
Siddiqui-Jain, A.; Drygin, D.; Streiner, N.; Chua, P.; Pierre, F.; O'Brien, S. E.; Bliesath, J.; Omori, M.; Huser, N.; Ho, C.;
Proffitt, C.; Schwaebe, M. K.; Ryckman, D. M.; Rice, W. G.; Anderes, K. Cancer Res. 2010, 70, 10288–10298.
Niefind, K.; Raaf, J.; Issinger, O. G. Cell. Mol. Life Sci. 2009, 66, 1800–1816.
7.
8.
9.
Trembley, J. H.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Cell. Mol. Life Sci. 2009, 66, 1858–1867.
Ahmad, K. A.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Adv. Enzyme Regul. 2008, 48, 179–187.
Ahmad, K. a; Wang, G.; Ahmed, K. Mol. Cancer Res. 2006, 4, 331–8.
Sarno, S.; Ghisellini, P.; Pinna, L. A. J. Biol. Chem. 2002, 277, 22509–22514.
Trembley, J. H.; Chen, Z.; Unger, G.; Slaton, J.; Kren, B. T.; Waes, C. Van; Ahmed, K. Biofectors. 2010, 36, 187–95.
Prudent, R.; Cochet, C. Chem. Biol. 2009, 16, 112–120.
Sarno, S.; de Moliner, E.; Ruzzene, M.; Pagano, M. A.; Battistutta, R.; Bain, J.; Fabbro, D.; Schoepfer, J.; Elliott, M.; Furet, P.;
Meggio, F.; Zanotti, G.; Pinna, L. A. Biochem. J. 2003, 374, 639–646.
10.
11.
12.
13.
14.
15.
16.
Faust, R. A.; Tawfic, S.; Davis, A. T.; Bubash, L. A.; Ahmed, K. Head Neck 2000, 22, 341–346.
Scott, J. W.; Galic, S.; Graham, K. L.; Foitzik, R.; Ling, N. X. Y.; Dite, T. A.; Issa, S. M. A.; Langendorf, C. G.; Weng, Q. P.;
Thomas, H. E.; Kay, T. W.; Birnberg, N. C.; Steinberg, G. R.; Kemp, B. E.; Oakhill, J. S. Chem. Biol. 2015, 22, 705–711.
Perera, Y.; Farina, H. G.; Hernández, I.; Mendoza, O.; Serrano, J. M.; Reyes, O.; Gómez, D. E.; Gómez, R. E.; Acevedo, B. E.;
Alonso, D. F.; Perea, S. E. Int. J. Cancer 2008, 122, 57–62.
17.
18.
19.
20.
21.
Raaf, J.; Brunstein, E.; Issinger, O. G.; Niefind, K. Chem. Biol. 2008, 15, 111–117.
Martel, V.; Filhol, O.; Colas, P.; Cochet, C. Oncogene 2006, 25, 7343–53.
Laudet, B.; Moucadel, V.; Prudent, R.; Filhol, O.; Wong, Y. S.; Royer, D.; Cochet, C. Mol. Cell. Biochem. 2008, 316, 63–69.
Laudet, B.; Barette, C.; Dulery, V.; Renaudet, O.; Dumy, P.; Metz, A.; Prudent, R.; Deshiere, A.; Dideberg, O.; Filhol, O.; Cochet,
C. Biochem. J. 2007, 408, 363–373.
22.
23.
24.
Brear, P.; De Fusco, C.; Hadje Georgiou, K.; Francis-Newton, N. J.; Stubbs, C. J.; Sore, H.; Venkitaraman, A.; Abell, C.; Spring,
D. R.; Hyvönen, M. Chem. Sci. 2016.
Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. J.
Med. Chem. 2006, 49, 6177–6196.
Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.;
Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739–1749.

25.
26.
Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. J. Med. Chem. 2004, 47,
1750–1759.
Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bolstad, E. S.; Coleman, R. G. ZINC: A free tool to discover chemistry for biology. J.
Chem. Inf. Model. 2012, 52, 1757–1768.
27.
28.
Brooijmans, N.; Chang, Y. W.; Mobilio, D.; Denny, R. A.; Humblet, C. Protein Sci. 2010, 19, 763–774.
Whittaker, M. Picking up the pieces with FBDD or FADD: invest early for future success. Drug Discov. Today 2009, 14, 623–
624.
29.
30.
31.
32.
Veber, D.F; Johnson, S.R; Cheng, H-Y; Smith, B.R; Ward, K.W; Kopple, K. D. J. Med. Chem. 2002, 45, 2615–2623.
Lolli, G.; Ranchio, A.; Battistutta, R. ACS Chem. Biol. 2014, 9, 366–371.
Niefind, K.; Guerra, B.; Ermakowa, I.; Issinger, O. G. EMBO J. 2001, 20, 5320–5331.
Lolli, G.; Pinna, L. A.; Battistutta, R. ACS Chem. Biol. 2012, 7, 1158–1163.
Supplementary Material
Data accessibility: all data supporting this study are provided as Supporting Information accompanying this paper.